Monograph
B01AC07 - Dipyridamole |
Not porphyrinogenic |
NP |
Rationale
No CYP-interactions. Three references consider it safe.
Chemical description
Platelet inhibitor administered as tablets in a dose of 200 mg, Maximal plasma levl is 2.6 ug/mL. In main parts excreted unmetabolized in faeces. Metabolism takes place by conjugation with glucuronic acid. South African list: Use. French list: Authorized. Michael Moore’s list: safe. C.Andersson; patient reports: tolerated (n=1)
IPNet drug reports
Uneventful use reported in 1 patients with acute porphyria.
Similar drugs
Tradenames and packages
From some sources, we get a list of packages (United Kingdom, Ireland, Estonia).
Other sources contain more or less "clean" versions of the trade name (Denmark, Finland, Iceland, Lithuania, Norway).
What you see here is the raw data we get from each country, so there will appear to be duplicates. The bold names
are the searchable terms. The gray names that follow are all mapped to the bolded term.
Note: The cleaning is done automatically by a proprietary algorithm, and it may produce errors.
We strive to improve it continuously.
Netherlands
United Kingdom
Denmark
Norway
Iceland
Finland
